NOK 14.0
(-6.35%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 19.93 Million NOK | 35.4% |
2022 | 14.72 Million NOK | 84.57% |
2021 | 7.97 Million NOK | 521.48% |
2020 | 1.28 Million NOK | -27.16% |
2019 | 1.76 Million NOK | 49.43% |
2018 | 1.17 Million NOK | -66.7% |
2017 | 3.54 Million NOK | 250.04% |
2016 | 1.01 Million NOK | 71.51% |
2015 | 589.81 Thousand NOK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 29.7 Million NOK | 77.5% |
2024 Q1 | 16.73 Million NOK | -16.07% |
2023 Q2 | 12.33 Million NOK | -22.4% |
2023 Q4 | 19.93 Million NOK | 59.26% |
2023 FY | 19.93 Million NOK | 35.4% |
2023 Q1 | 15.89 Million NOK | 7.97% |
2023 Q3 | 12.51 Million NOK | 1.47% |
2022 Q3 | 14.37 Million NOK | -5.12% |
2022 FY | 14.72 Million NOK | 84.57% |
2022 Q2 | 15.14 Million NOK | 0.0% |
2022 Q4 | 14.72 Million NOK | 2.45% |
2021 Q4 | 7.97 Million NOK | 0.0% |
2021 FY | 7.97 Million NOK | 521.48% |
2021 Q2 | 5.58 Million NOK | 0.0% |
2020 Q4 | 1.28 Million NOK | 0.0% |
2020 FY | 1.28 Million NOK | -27.16% |
2019 Q4 | 1.76 Million NOK | 0.0% |
2019 Q2 | 292.41 Thousand NOK | 0.0% |
2019 FY | 1.76 Million NOK | 49.43% |
2018 Q4 | 1.17 Million NOK | 0.0% |
2018 Q2 | 4.96 Million NOK | 0.0% |
2018 FY | 1.17 Million NOK | -66.7% |
2017 FY | 3.54 Million NOK | 250.04% |
2017 Q4 | 3.54 Million NOK | 0.0% |
2016 FY | 1.01 Million NOK | 71.51% |
2015 FY | 589.81 Thousand NOK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Gentian Diagnostics ASA | 33.65 Million NOK | 40.764% |
Medistim ASA | 107.77 Million NOK | 81.503% |